Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Hepatitis C

Hepatitis C

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV).
It can range from a mild illness lasting a few weeks to a serious, lifelong condition.
Many people with hepatitis C have no symptoms, but it can lead to cirrhosis, liver cancer, and other serious health problems.
PubCompare.ai can help optimize your hepatitis C research by locating protocols from literature, pre-prints, and patents, and leveraging AI-driven comparisons to identify the best protocols and products.
This can streamline your research process and keep you ahead of the curve in this fast-paced field.

Most cited protocols related to «Hepatitis C»

1
Comprehensive Evaluation of Fatty Liver Disease
Besides a clinical and laboratory evaluation, each subject underwent a liver ultrasonography, an anthropometric assessment and a 7-day diary of food intake (7DD) [1 (link)]. HBsAg and anti-HCV antibodies were assessed and subjects with anti-HCV antibodies underwent an HCV-RNA assessment to confirm HCV infection [1 (link),14 (link)]. ALT, aspartate transaminase (AST), GGT, glucose, triglycerides and cholesterol were measured by standard laboratory methods after 8-hr fasting. Insulin was measured by radio-immuno-assay (ADVIA Insulin Ready Pack 100, Bayer Diagnostics, Milan, Italy), with intra- and inter-assay coefficients of variation < 5%. FL was diagnosed by the same operator at ultrasonography [6 (link)]. Weight, stature, circumferences (waist and hip) and skinfolds (triceps, biceps, subscapular and suprailiac) were measured by two trained dietitians who had been standardized before and during the study according to standard procedures [15 ]. Body mass index (BMI) was calculated as weight (kg)/stature (m)2 and the sum of 4 skinfolds by summing triceps, biceps, subscapular and suprailiac skinfolds [16 (link),17 (link)]. The 7DD was administered to the subjects by two trained dietitians, who discussed it with the subject when she/he returned it one week later [18 (link)]. To avoid the confounding effect of seasonality on food intake, the 7DD diary was administered to a similar number of patients with and without SLD each month [19 ]. Mean daily ethanol intake was calculated as the mean value of ethanol intake as assessed by the 7DD [20 ]. The study protocol was approved and supervised by the Scientific Committee of the Fondo per lo Studio delle Malattie del Fegato (Trieste, Italy), and all subjects gave their written informed consent to participate.
Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A, & Tiribelli C. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 33.
Full text: Click here
Publication 2006
Aspartate Transaminase Biological Assay Body Height Cholesterol Dietitian Eating Ethanol Glucose Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Index, Body Mass Insulin Liver Patients Radioimmunoassay Triglycerides Ultrasonography
2
Dionysos Nutrition and Liver Study
The protocol of the Dionysos Nutrition & Liver Study was described in detail elsewhere [1 (link)]. Briefly, of 5780 residents of Campogalliano (Modena, Italy) aged 18 to 75 years, 3345 (58%) agreed to participate to the study; 3329 (99%) of them had all the data required by the Dionysos Project [7 (link),13 (link)] and were considered for further analysis. 497 (15%) of them had suspected liver disease (SLD) according to at least one of the following criteria: 1) alanine transaminase (ALT) > 30 U*L-1; 2) gamma-glutamyl-transferase (GGT) > 35 U*L-1; 3) presence of hepatitis B surface antigen (HBsAg); 4) presence of Hepatitis C (HCV) virus ribonucleic acid (RNA) after detection of anti-HCV antibodies. The 497 subjects with SLD were matched with an equal number of subjects of the same age and sex but without SLD, randomly selected among the remaining 2832 subjects. After exclusion of subjects with HBV or HCV infection, the original analysis was performed on 224 subjects with and 287 without SLD [1 (link)]. The present analysis is performed on 216 (96%) subjects with and 280 (97%) without SLD, based on the availability of skinfold measurements.
Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A, & Tiribelli C. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 33.
Full text: Click here
Publication 2006
Alanine Transaminase gamma-Glutamyl Transpeptidase Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Liver Diseases Liver Function Tests RNA Virus
3
Hepatitis C Antiviral Long-Term Trial against Cirrhosis
The design of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial has been described previously.12 (link) Briefly, patients meeting the following criteria were entered into this study from 10 study centers in the United States between August 2000 and August 2004: lack of a sustained virologic response to previous therapy, advanced hepatic fibrosis according to liver biopsy (an Ishak fibrosis score13 (link) of 3 or more; scores range from 0 to 6, with higher scores indicating greater degrees of fibrosis and scores of 5 or 6 indicating cirrhosis), no history of hepatic decompensation or hepatocellular carcinoma, and absence of exclusion criteria (e.g., liver disease other than hepatitis C, uncontrolled medical or psychiatric conditions, or contraindications to interferon treatment). The patients were stratified according to their Ishak fibrosis score. The non-cirrhotic-fibrosis stratum consisted of 622 patients with a score of 3 or 4, and the cirrhosis stratum consisted of 428 patients with a score of 5 or 6. The patients provided written informed consent for participation in the trial.
During the lead-in phase of the trial, all patients underwent treatment with 180 μg of subcutaneous pegylated interferon alfa-2a weekly (Pegasys, Roche; the drug had not yet been approved by the Food and Drug Administration [FDA] when the trial began) and oral ribavirin (1000 to 1200 mg daily, according to body weight) for at least 24 weeks before undergoing randomization (Fig. 1). Randomization was stratified according to clinical center and the presence or absence of cirrhosis and was performed centrally by computer with the use of permuted blocks of random size. Patients with detectable serum HCV RNA levels at treatment week 20 were classified as having no response (<1 log10 IU per milliliter decrease in HCV RNA level from baseline) or a partial response (≥1 log10 IU per milliliter decrease in HCV RNA level from baseline) and were assigned for the next 3.5 years to either the maintenance-therapy group (90 μg of peginterferon alfa-2a weekly, without ribavirin) or the untreated control group. For treated patients who had unacceptable side effects, the weekly peginterferon dose was reduced to 45 μg or even lower, as needed.
Patients with undetectable serum HCV RNA at week 20 continued therapy for an additional 48 weeks, as reported previously.14 (link) If HCV RNA was detected in a patient again after week 20, either during treatment (breakthrough) or after cessation of treatment (relapse), the patient was offered the opportunity to undergo randomization in the controlled phase of the trial (the “breakthrough or relapse” cohort). During the trial, after pegylated interferons became available for treating hepatitis C, we amended the protocol to allow patients who had been treated with peginterferon plus ribavirin outside the study but had not had a sustained virologic response to treatment to undergo randomization to the treatment or control group (the “express” cohort).
Di Bisceglie A.M., Shiffman M.L., Everson G.T., Lindsay K.L., Everhart J.E., Wright E.C., Lee W.M., Lok A.S., Bonkovsky H.L., Morgan T.R., Ghany M.G., Morishima C., Snow K.K, & Dienstag J.L. (2008). Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. The New England journal of medicine, 359(23), 2429-2441.
Publication 2008
Antiviral Agents Biopsy Body Weight Fibrosis Fibrosis, Liver Hepatitis C Hepatocellular Carcinomas Interferons Liver Liver Cirrhosis Liver Diseases Long-Term Care Mental Disorders Patients Pegasys peginterferon alfa-2a Pharmaceutical Preparations Relapse Ribavirin Serum Withholding Treatment
4
Chronic Drug-Induced Liver Injury Protocol
Chronic DILI is defined at 6 months after DILI onset as one of the following: (i) for subjects with normal or unknown baseline liver biochemistries, a serum AST, ALT, alkaline phosphatase, INR or total bilirubin that is persistently elevated on two separate occasions; (ii) for liver DILI subjects, a serum AST, ALT, alkaline phosphatase, INR or total bilirubin level that exceeds 1.25 times the baseline value on two separate occasions; (iii) any evidence of portal hypertension such as ascites on imaging, varices on upper endoscopy or clinical evidence of hepatic encephalopathy; (iv) any histological evidence of persistent liver injury at least 6 months after DILI onset; or (v) any radiological evidence of chronic liver disease such as ascites, hepatomegaly, nodular liver or intra-abdominal varices. Subjects with pre-existing chronic HBV or HCV infection, liver transplant recipients since the baseline visit and patients with cirrhosis or clinical evidence of portal hypertension before starting the suspect medication are excluded from the chronic DILI protocol.
Subjects with chronic DILI are seen at 12 and 24 months after the baseline visit wherein incremental medical history, medication use, laboratory and imaging studies and questionnaires are completed. A final written narrative is also generated by the site investigator summarizing the course of the DILI episode. For subjects who die during follow-up, a death narrative recording whether the death was attributable to a liver or non-liver related cause is generated by the site investigator for review by the causality committee.
Fontana R.J., Watkins P.B., Bonkovsky H.L., Chalasani N., Davern T., Serrano J, & Rochon J. (2009). Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct. Drug safety : an international journal of medical toxicology and drug experience, 32(1), 55-68.
Publication 2009
Abdominal Cavity Alkaline Phosphatase Ascites Bilirubin Endoscopy, Gastrointestinal Hepatic Encephalopathy Hepatitis C Injuries Liver Liver Cirrhosis Liver Diseases Liver Transplantations Patients Pharmaceutical Preparations Portal Hypertension Serum Transplant Recipients Varices Vision X-Rays, Diagnostic
5
Plasmid Construction and Fluorescent Protein Tagging
All plasmids were constructed using the pEGFP-C1 or -N1 backbone (Takara Bio Inc.). When different fluors were used, EGFP was replaced with CFP, mTq2 (mTurquoise2; a gift from T. Gadella, University of Amsterdam, Amsterdam, Netherlands; Goedhart et al., 2012 (link)), mRFP (Campbell et al., 2002 (link)), mCherry (Shaner et al., 2004 (link)), or iRFP (Filonov et al., 2011 (link)).
The following cDNAs were amplified by PCR and subcloned into plasmids as follows: residues 546–647 from L. pneumophila SidM (available from GenBank under accession no. DQ845395), corresponding to the isolated P4M domain (Schoebel et al., 2010 (link)), were cloned into pEGFP-C1 (or spectral variants mCherry or iRFP) at BspEI and EcoRI sites. We also made a similar plasmid inserting the same P4M fragment at SalI and BamHI sites with a GGSASGLRS linker between GFP and the N terminus. This was used as a template to insert a second P4M insert at EcoRI and SalI sites with the same linker between GFP and the first P4M and a GGSAVDGGSASGLRS linker separating the tandem P4M domains. To generate FRB fused to canine Rab5 and Rab7 (a gift from R. Lodge, Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada; Rojas et al., 2008 (link)), the entire coding regions were inserted at HindIII–KpnI sites of a modified piRFP-C1 vector containing the FRB domain (NCBI Nucleotide accession no. NM_004958; residues 2,021–2,113) flanked by GGAGA and GGSAGGSA linkers at the 5′ and 3′ ends, respectively, and inserted at BglII–HindIII sites. For pmCherry-C1-FKBP-MTM1, FKBP (NCBI Nucleotide accession no. NM_054014; residues 3–109) flanked by GAGGAARAAL and (SAGG)5PRAQASNSA linkers at the 5′ and 3′ ends were inserted at NotI–SalI sites and MTM1(NCBI Nucleotide accession no. NM_000252) at SalI–BamHI. Hepatitis C NS5A (Budhu et al., 2007 (link)) was obtained from Addgene and inserted at HindIII–KpnI sites in pmCherry-N1. piRFP-N1-TTC7B (isolated from an EST that misses L53-A85 from exon 2; GenBank accession no. BQ426031) was inserted at NheI–SalI sites with a C-terminal GGSAGGSA linker with the iRFP. Constructs are available through Addgene. PI4KAv1 (NCBI Nucleotide accession no. NM_058004) was inserted at EcoRI–SalI sites of pmTq2-C1, and PI4KBv2 (NCBI Nucleotide accession no. NM_001198773) was inserted at XhoI–KpnI sites in pEGFP-C1. pEGFP-N1-EFR3B (NCBI Nucleotide accession no. NM_014971) was inserted at NheI–AgeI sites. Murine Sacm1l (NCBI Nucleotide accession no. NM_030692) was inserted at BglII–SalI sites in pmCherry-N1. Additional plasmids were obtained as follows: pEGFP-N1-PH-PLCδ1 (Várnai and Balla, 1998 (link)); pEGFP-N1-PH-FAPP1 and pEGFP-C1-PH-OSBP (Balla et al., 2005 (link)); PJ, its catalytic mutants, and pECFP-N1-Lyn11-FRB (Hammond et al., 2012 (link)); pmRFP-FKBP-INPP5E (Várnai et al., 2006 (link)); pECFP-FRB-giantin3,140–3,269 (a gift from T. Inoue, Johns Hopkins University School of Medicine, Baltimore, MD; Komatsu et al., 2010 (link)) or a pmCherry variant; pECFP-C1-FKBP-PIP5K (Suh et al., 2006 (link)); pmCherry-C1-Rab5 and -Rab7 (Rojas et al., 2008 (link)); GFP-FYVE-EEA1 (Balla et al., 2000 (link)); pEGFP-N1-PI4K2A (Jović et al., 2012 (link)); pEGFP-N1-PI4K2B (Balla et al., 2002 (link)); and piRFP-C1-PH-PLCδ1 (a gift from P. De Camilli, Yale School of Medicine, New Haven, CT; Idevall-Hagren et al., 2012 (link)).
Hammond G.R., Machner M.P, & Balla T. (2014). A novel probe for phosphatidylinositol 4-phosphate reveals multiple pools beyond the Golgi. The Journal of Cell Biology, 205(1), 113-126.
Publication 2014
Canis familiaris Catalysis Cloning Vectors Deoxyribonuclease EcoRI DNA, Complementary Exons Hepatitis C Mus Nucleotides Plasmids Tacrolimus Binding Proteins Vertebral Column X-Linked Centronuclear Myopathy

Most recents protocols related to «Hepatitis C»

1
HBV Prevalence in Correctional Facilities
The work group used an existing literature search of articles on HBV and HCV infections in correctional and detention facilities. The search period was January 1, 2000 through March 3, 2021 (Supplementary Table 8, https://stacks.cdc.gov/view/cdc/124432). Abstracts were reviewed by two reviewers (AH, LH, JB, OR, or EC) for relevance, and discrepancies in inclusion were resolved by the first author (EC) or by consensus discussion. Only articles containing incidence or prevalence of HBV infection among persons with a history of incarceration or incarceration as a risk factor for HBV infection were included in this review (Supplementary Table 9, https://stacks.cdc.gov/view/cdc/124432). Data from the included full text articles or abstracts were independently abstracted by two reviewers (LP and EC) and differences were resolved by consensus discussion. Because of the limited amount of literature available about HBV infection in correctional settings, the work group included conference abstracts, which are labeled as such because of their presumed lower quality. The quality of the articles was assessed using MMAT. The population was considered at “increased risk” if the prevalence of HBV infection was ≥1%.
Conners E.E., Panagiotakopoulos L., Hofmeister M.G., Spradling P.R., Hagan L.M., Harris A.M., Rogers-Brown J.S., Wester C., Nelson N.P., Rapposelli K., Sandul A.L., Choi E., Coffin C., Marks K., Thomas D.L, & Wang S.H. (2023). Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023. MMWR Recommendations and Reports, 72(1), 1-25.
Full text: Click here
Publication 2023
Conferences Hepatitis C Infection
2
Substance Use and HIV Outcomes
Demographic data were collected by self-report, including age, ethnicity, household annual income, and highest level of education. For participants under 19 years of age, income and education data were not collected.
Substance use data were collected by self-report. Tobacco use was trichotomized as current, past, or never. Current methadone use, other prescription opioid use, and heroin use were collected as binary variables (yes/no), then combined into a single current opioid use variable.
HIV clinical data were collected from medical records, including HIV plasma viral load (pVL), highest HIV pVL ever recorded, CD4+ cell count, and CD4+ nadir. HCV infection ever was self-reported for all participants and confirmed via medical chart review for WWH.
Van Ommen C.E., Hsieh A.Y., Albert A.Y., Kimmel E.R., Cote H.C., Maan E.J., Prior J.C., Pick N, & Murray M.C. (2023). Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women. AIDS (London, England), 37(5), 769-778.
Publication 2023
CD4+ Cell Counts Ethnicity Hepatitis C Heroin Households Methadone Opioids Plasma Substance Use
3
Comparative Analysis of Predicted HLA-A*02:01 Epitopes
We scanned the sequence of the Hepatitis C virus (HCV) genome polyprotein (3,011 amino acids; Uniprot ID P27958) to find potential 10-mer peptide epitopes presented by HLA-A*02:01. We ran NetMHCpan with FASTA format input and default parameters. NetMHCpan compares 10-mer peptides to its internal 9-mer binding model by dropping one gap position from the peptide:model alignment. We parsed the location of the gap position from the output columns (“Of”, “Gp”, and “Gl”) and confirmed by matching to the sequence in the “Core” column. To assess divergence between our structure-based predictions and NetMHCpan, raw scores from each method were sorted and converted to rank scores. Peptides were grouped by the NetMHCpan-assigned gap position, and the mean absolute difference in rank score was computed for each gap position.
Motmaen A., Dauparas J., Baek M., Abedi M.H., Baker D, & Bradley P. (2023). Peptide-binding specificity prediction using fine-tuned protein structure prediction networks. Proceedings of the National Academy of Sciences of the United States of America, 120(9), e2216697120.
Full text: Click here
Publication 2023
Amino Acids Epitopes Genome gonadotropin releasing hormone associated peptide Hepatitis C Peptides Polyproteins
4
HCV Genotype 4 Treatment Outcomes
The participants included male and female patients 18 years and older with HCV infection, any level of detectable HCV RNA, and a documented HCV GT4 infection. As data were collected retrospectively, patients with missing data were excluded from the study. All cirrhotic participants were assigned a child pugh (CP) score based on clinical and laboratory data and model for end stage liver disease (MELD) score based on laboratory data. Cirrhosis and non-cirrhosis was defined by clinical, radiological features, and liver stiffness assessed by transient elastography with a value >12.5 kpa and <12.5 kpa, respectively, within 6 months of screening.[10 (link)-12 (link)] Patients with decompensated cirrhosis were excluded as GZR is contraindicated in this population. HBV coinfected patients are of risk of reactivation of HBV and fulminant liver failure including death with DAA treatment. For treatment experienced, a different study protocol may be needed and hence not included in this study. None of our participants were found to have HCC, HIV coinfection, HBV coinfection, and past history of treatment with interferon and DAA and hence, they were not included in this study.
Murgod S.E., Ahmed S., Almutairi N., Alqifari A., Alharbi M, & Shoqueer A. (2023). Safety and efficacy of elbasvir/grazoprevir in patients infected with hepatitis C virus genotype 4 in Qassim region of Saudi Arabia. International Journal of Health Sciences, 17(2), 22-27.
Publication 2023
Child Coinfection Elasticity Imaging Techniques End Stage Liver Disease Hepatitis C HIV Coinfection Interferons Liver Liver Cirrhosis Liver Failure, Acute Males Patients Transients Woman X-Rays, Diagnostic
5
Hepatic Steatosis Assessment via FibroScan
Hepatic steatosis was assessed using FibroScan® which uses ultrasound and VCTE to measure the controlled attenuation parameter (CAP). Hepatic steatosis was categorized based on the median CAP dB/m for steatosis grades into S0 (no steatosis) < 238; S1 (mild steatosis) = 238–259; S2 (moderate steatosis) = 260–290; and S3 (severe steatosis) > 290 (MSKC Center, 2018 ). For classification of NAFLD, subjects were considered to have NAFLD if they had hepatic steatosis and did not have any exclusion criteria [transferrin level >50%, hepatitis B, hepatitis C, excessive alcohol use (i.e., an average of more than two drinks/day for men or one drink/day for women), or prescription medications that might cause hepatic steatosis (i.e., corticosteroids, antiarrhythmics, anticancer-antimetabolites, anticancer-hormonal drugs, anti-convulsant drugs, or nucleoside/nucleotide reverse transcriptase inhibitors)] (Kim et al., 2022 (link)).
Shaheen M., Schrode K.M., Tedlos M., Pan D., Najjar S.M, & Friedman T.C. (2023). Racial/ethnic and gender disparity in the severity of NAFLD among people with diabetes or prediabetes. Frontiers in Physiology, 14, 1076730.
Full text: Click here
Publication 2023
Adrenal Cortex Hormones Anti-Arrhythmia Agents Antimetabolites Convulsants Hepatitis B Hepatitis C Non-alcoholic Fatty Liver Disease Nucleosides Nucleotides Pharmaceutical Preparations Prescription Drugs Reverse Transcriptase Inhibitors Steatohepatitis Transferrin Ultrasonics Woman

Top products related to «Hepatitis C»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
4
Fibroscan by Echosens
Sourced in France, United States
FibroScan is a non-invasive diagnostic device that uses vibration-controlled transient elastography (VCTE) technology to measure liver stiffness. The device transmits a mild vibration through the skin and measures the velocity of the resulting shear wave, which is directly related to the stiffness of the liver tissue. This information can be used to assess the degree of liver fibrosis.
5
Cobas ampliprep cobas taqman hcv test by Roche
Sourced in United States, Germany, Japan
The COBAS AmpliPrep/COBAS TaqMan HCV Test is a diagnostic laboratory equipment product designed for the detection and quantification of Hepatitis C Virus (HCV) RNA in human serum or plasma samples. It utilizes real-time PCR technology to provide automated sample preparation and amplification, delivering reliable and accurate results.
6
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
7
Spss version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
8
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
9
Stata 13 by StataCorp
Sourced in United States, Denmark, United Kingdom, Austria, Sweden
Stata 13 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphical capabilities. Stata 13 is designed to handle complex data structures and offers a variety of statistical methods for researchers and analysts.

More about "Hepatitis C"

Hepatitis C is a serious liver disease caused by the hepatitis C virus (HCV).
This chronic condition can range from a mild illness lasting a few weeks to a lifelong, potentially life-threatening condition.
Many individuals with hepatitis C are asymptomatic, but the disease can lead to severe complications like cirrhosis, liver cancer, and other health problems.
To optimize research on hepatitis C, PubCompare.ai is a powerful AI-driven platform that can help researchers locate relevant protocols from literature, preprints, and patents.
The platform leverages advanced AI algorithms to compare these protocols, enabling researchers to identify the best and most effective approaches.
This streamlined research process can keep researchers ahead of the curve in the fast-paced field of hepatitis C.
PubCompare.ai's capabilities extend beyond just hepatitis C, and can be applied to a wide range of medical and scientific topics.
In addition to PubCompare.ai, other relevant tools and technologies for hepatitis C research include SAS version 9.4, FibroScan, COBAS AmpliPrep/COBAS TaqMan HCV Test, and SPSS version 20.
These tools can be used for data analysis, disease staging, and viral load testing, among other applications.
By leveraging the power of AI and these advanced technologies, researchers can delve deeper into the complex world of hepatitis C, uncover new insights, and develop more effective treatments and interventions.
Stay ahead of the curve and optimize your hepatitis C research with the help of PubCompare.ai and other cutting-edge tools.